HER-2/neu gene amplification, found in certain subtypes of (breast-) cancers, is an independent prognostic factor of poor outcome and determines eligibility for systemic treatment with trastuzumab. TopoIIa (TOP2A) gene amplification seems to be predictive of response to a class of cytostatic agents called TopoII inhibitors, which include the anthracyclines. The observed increased efficacy of anthracyclines in HER2-positive tumors is thought to arise from the close proximity of both genes on chromosome 17, where the TopoII amplification status will determine the anthracycline sensitivity. This study aimed to validate a new polymerase chain reaction-based test, called multiplex ligation-dependent probe amplification (MLPA), as a simple and quick method to simultaneously assess HER-2/neu and TopoIIa gene amplification status in paraffin-embedded breast cancer samples. To this end, MLPA results were compared with TopoIIa, HER2 chromogenic in situ hybridization (CISH). We also assessed TopoIIa protein expression by immunohistochemistry. Of 353 patients, 9% showed TopoIIa amplification by MLPA and 13% of patients were HER2 amplified. TopoIIa amplification was seen in 42% of HER2-amplified cases and showed no high level amplification without HER2 amplification. Eleven patients displayed TopoIIa loss (3%). Concordance between MLPA and CISH was 91% for TopoIIa and 96% for HER2. Correlation between amplification and overexpression of TopoIIa was significant (P ¼ 0.035), but amplification did not always predict protein overexpression. Loss of the TopoIIa gene was almost never associated with loss of its protein. In conclusion, MLPA is an easy and accurate method to simultaneously detect breast cancer HER-2/neu and TopoIIa copy number status in paraffin-embedded tissue, and thus an attractive supplement or alternative to CISH.
The topoisomerase IIa (TopoIIa, TOP2A) gene is located at chromosome 17q21.2 and encodes a 170 kDa protein that has a key role in cell division by controlling and modifying the topological status of DNA. 1 Furthermore, TopoIIa is the direct molecular target of TopoII inhibitors including anthracyclines, which are among the most powerful cytostatic agents in the treatment of invasive breast cancer. The binding of anthracyclines to TopoIIa is believed to stabilize the DNA double-strand breaks created by TopoIIa, leading to apoptosis. The TopoIIa gene is located next to the locus of the HER2 (human epidermal growth factor receptor 2) gene, a proto-oncogene belonging to the EGFR family. The HER2 gene encodes for a 185-kDa transmembrane glycoprotein, and overexpression of the protein is associated with poor prognostic as a consequence of increased cell proliferation, angiogenesis, invasive growth, and resistance to apoptosis. The HER2 gene is amplified and overexpressed in 10-30% of breast cancers, in which it has an important role in oncogenesis. 2, 3 The HER2 protein is a direct target of trastuzumab (Herceptin R ), a humanized monoclonal antibody that has been approved for the systemic treatment of both primary and metastatic breast cancer. [4] [5] [6] With regard to the sensitivity of HER2-positive breast cancer, a number of studies have suggested an association with increased benefit of anthracycline-containing regimens. As a molecular basis for this association seems difficult to grasp, it has been suggested that the increased sensitivity of HER2/neu-positive breast cancer is a result from the proximity of the TopoIIa gene to the HER2 gene. 7 Overall, TopoIIa amplification is considered to be an uncommon event in breast cancer, with a prevalence of approximately 5-10%. 8, 9 Co-amplification of HER2 and TopoIIa is seen in approximately 40% of HER2-amplified breast cancer patients 10, 11 and results of-mainly retrospectively obtained-data seem to underline the hypothesis that TopoIIa and not HER2 overexpression is the ultimate predictor of the response to anthracyclines. 10, [12] [13] [14] Measurement of TopoIIa in the tumor could therefore potentially be useful in selecting the patients for treatment with TopoII inhibitors, including anthracyclines. Expression of TopoIIa protein has, however, not been shown to reliably predict response to anthracyclines, despite the fact that it is the direct target for these compounds. 11, [15] [16] [17] In contrast, evaluation of TopoIIa gene copy number appears to be a good predictor of response to TopoIIa inhibitors. [18] [19] [20] Furthermore, contrary to HER2, TopoIIa amplification has shown an inconsistent correlation with TopoIIa protein expression, 21, 22 mainly because TopoIIa protein is highly dependent on the stage of the cell cycle and proliferation rate.
Recently, we introduced HER2 amplification detection in breast cancer by multiplex ligationdependent probe amplification (MLPA). MLPA kits contain probes for up to 45 different targets allowing copy number assessment of different genes in the same PCR. 23 MLPA requires only small quantities of short DNA fragments, which makes it very suitable for analysis of paraffin-embedded material. In previous studies using MLPA, we obtained promising results for HER2 in comparison with immunohistochemistry, 24 fluorescence in situ hybridization and chromogenic in situ hybridization (CISH). 25 As the applied HER2 kit also contains a TopoIIa probe, we set out to test MLPA as a new method to simultaneously assess HER2 and TopoIIa gene amplification status in a large group of breast cancer patients and to validate MLPA results with CISH in a subgroup of these patients. In addition, we investigated the correlation between TopoIIa protein expression levels and gene amplification status on tissue micro arrays, using immunohistochemistry and CISH, respectively.
Materials and methods

Patient Material
From a previously used study cohort (n ¼ 518), collected between November 2004 and June 2006 at the Department of Pathology of the University Medical Centre in Utrecht, 25 353 consecutive tissue samples of invasive breast cancer patients were randomly selected. First, all tissue samples were analyzed by MLPA to determine HER2 and TopoIIa gene amplification status. For TopoIIa CISH and immunohistochemistry, tissue microarrays were constructed from the original paraffin-embedded tumor blocks (n ¼ 315) using published guidelines. 26 In this study, the use of left over material was approved by the Tissue Science Committee of the UMC Utrecht.
Multiplex Ligation-Dependent Probe Amplification
Invasive tumor areas were harvested from 4 mm thick paraffin sections by dissection with a scalpel (using at least 1 cm 2 tumor tissue) and DNA was isolated by 1 h incubation in proteinase K (10 mg/ml; Roche, Almere, The Netherlands) at 561C followed by boiling for 10 min. This DNA solution (50-100 ml) was, after centrifugation, used in the MLPA analysis according the manufacturers' instructions, using the P004-A1 HER2 kit (MRC Holland, Amsterdam, The Netherlands). This kit contains three probes for the HER2 gene, a probe for TopoIIa, 9 additional control probes for chromosome 17, and 25 control probes located on other chromosomes. Details of the probes in this kit can be found at http://www.mrc-holland.-com. All tests were performed in duplicate on an ABI 9700 PCR machine (Applied Biosystems, Foster City, CA, USA). PCR products were analyzed on an ABI310 capillary sequencer. HER2 and TopoIIa gene copy numbers were normalized against the control probes in the kit, thereby excluding all chromosome 17 probes. The mean of all three HER2 probe peaks in duplicate (6 values) and the TopoIIa peak in duplicate (2 values) was calculated. If this mean value was below 0.7, TopoIIa or HER2 was considered lost, values between 0.7-1.5 were considered normal, values between 1.5 and 2.0 as low level amplified, and values 42.0 as HER2 or TopoIIa amplified. The 2.0 threshold was used in accordance with previous HER2 MLPA studies, 24, 27 whereas the 1.5 threshold was empirically established during routine diagnostic application of MLPA kits for trisomy detection.
Chromogenic In Situ Hybridization
HER2 and TopoIIa CISH assays were performed on 4 mm thick paraffin serial tissue array sections using the SPoT-Light HER2 or TopoIIa kits (Zymed, San Francisco, CA, USA) according to the manufac-TOP2A and HER2 gene amplification in breast cancer CB Moelans et al turers' instructions. First, sections were baked overnight at 561C and deparaffinized in xylene and alcohol 100%. For HER2 and TopoIIa, the slides were then boiled in pretreatment buffer for 15 min, followed by enzymatic digestion at room temperature (RT) for 10 min (Zymed). Then, slides were dehydrated with graded alcohols. After 20 min of air-drying, the digoxigenin-labeled TopoIIa or HER2 probes were applied to the slides. Then, the sections were denatured on a hot plate (951C) for 5 min and hybridization was carried out overnight at 371C. After hybridization, appropriate stringency washes at 801C were performed, followed by blocking with 3% hydrogen peroxide and CAS block (Zymed). Subsequently, the slides were incubated with mouse-anti-digoxigenin antibody (Zymed) for 30 min at RT and goat-anti-mouse antibody conjugated with horseradish peroxidase (HRP) for 30 min at RT. This was followed by diaminobenzidine (DAB) development for 30 min and counterstaining with hematoxylin. Finally, sections were dehydrated and mounted in Histomount (Zymed). A positive control was included in each CISH run and consisted of paraffin sections of a case known to be TopoIIa/HER2 amplified by CISH. At least 30 preferably non-overlapping nuclei in every tumor sample were scored by two blinded observers to determine the number of HER2 and TopoIIa signals. Amplification was defined to be present when large peroxidase-positive intra-nuclear clusters (or 410 individual small signals) were detected in at least 50% of tumor cells. The presence of small peroxidase-positive intra-nuclear clusters (or 6-10 individual small signals) was considered low level amplified. One to five individual small signals were scored as HER2/TopoIIa non-amplified.
Immunohistochemistry
Immunohistochemistry was performed using a mouse monoclonal antibody against the TopoIIa protein (clone Ki-S1, DAKO, Glostrup, Denmark) on 4 mm thick sections from neutral-buffered formaldehyde-fixed tissue array blocks. First, sections were baked overnight at 561C, deparaffinized and rehydrated. The slides were then blocked in 3% hydrogen peroxide for 15 min and boiled in EDTA buffer (pH 9.0) for 20 min. After washing in 0.05% PBS Tween, the slides were incubated with the primary antibody at a dilution of 1/200 for 60 min at RT. Detection was performed with Envision (Dako, Glostrup, Denmark) using an HRP-conjugated secondary antibody followed by DAB development. The percentage of strongly positive nuclei was estimated (weakly positive nuclei were ignored). The median percentage of stained cells was 2%, we therefore defined 42% as overexpression. Immunohistochemistry expression was analyzed by one experienced (blinded) breast pathologist (PJvD) and at least 30 nuclei were scored.
Statistics
Results obtained with MLPA and CISH were compared by cross tables using SPSS for Windows and the concordance percentages were calculated. Correlations between continuous and categorical variables were performed with the non-parametric Mann-Whitney U-test. Correlations between categorical variables were performed using the w 2 -test. P-values below 0.05 were considered significant.
Results
Multiplex Ligation-Dependent Probe Amplification Table 1 shows the frequencies of TopoIIa and HER2 amplification. The TopoIIa gene was low level amplified in 7% of cases and highly amplified in 8 cases (2%), adding up to a total of 33/353 (9%) cases with amplification. HER2 was low level amplified in 10/353 cases (3%) and highly amplified in 34/353 cases (10%), adding up to a total of 44/353 (13%) of amplified cases.
Co-amplification with TopoIIa was seen in 42% of HER2-amplified cases (including both low and high levels). There was no high level amplification of TopoIIa without HER2 amplification. However, in some cases we found a low level amplification of TopoIIa without amplification of HER2. As to comparative copy numbers in co-amplified tumors, HER2 was often amplified at a higher level than TopoIIa within the same tumor.
Eleven cases (3%) were deleted for TopoIIa, all having a normal HER2 status.
Chromogenic In Situ Hybridization
TopoIIa and HER2 CISH were performed on 284 patients who were analyzed by MLPA (see Table 2 ). Sensitivity, specificity, positive-predictive value and negative-predictive value of MLPA for HER2 and TopoIIa were calculated and depicted in Table 4 using CISH results as gold standard, and by taking low level and high level amplifications together. When the cut-off was set at 1.8, the number of low level amplified patients was reduced significantly, thereby increasing the concordance between MLPA and CISH (as gold standard) for TopoIIa. Nevertheless, increasing the cut-off value lead to a decrease in sensitivity of MLPA for both genes.
Immunohistochemistry
From tissue arrays containing cores of 315 patients, information for both immunohistochemistry and CISH was obtained for 265 patients. A strong positive nuclear staining for Topoisomerase IIa in 265 invasive breast tumors ranged from 0 to 90% of tumor cells. One hundred and seventeen cases (44%) showed overexpression. Topoisomerase IIa overexpression was significantly associated with TopoIIa amplification by MLPA (P ¼ 0.035), although 4/14 (29%) of amplified tumors did not overexpress the TopoIIa protein (Table 3, Figure 1 ). One patient showing amplification of TopoIIa by CISH was not analyzed by immunohistochemistry because there was not enough tissue left. Of the cases without TopoIIa amplification, 42% showed overexpression, in comparison with 71% for TopoIIa-amplified cases. There was also evidence of a difference (P ¼ 0.01) in the mean TopoIIa protein expression level for tumor samples with TopoIIa amplification by CISH (n ¼ 14, mean 28% immunohistochemistry positive) vs no TopoIIa gene amplification (n ¼ 251, mean 7% immunohistochemistry positive).
Loss of the TopoIIa gene (n ¼ 15) was rarely (2/15) accompanied by absence of its protein, but rather by overexpression (7/15) although not significantly (P ¼ 0.421).
Discussion
The aim of this study was to test MLPA as a new method to simultaneously assess HER2 and TopoIIa gene amplification status in a large group of breast cancer patients, and to compare MLPA results with CISH data as gold standard in a selected group of patients. Of 353 patients analyzed by MLPA, 2% showed a high level amplification of the TopoIIa gene and 10% of patients manifested a high level amplification of the HER2 gene. When including low amplification, the percentages of amplification rose to 9 and 13%, respectively. For HER2 this is lower than the 20-30% positivity that has generally been described in the literature, 2, 3, 28, 29 although several other studies have reported lower (10-18%) percentages [30] [31] [32] [33] [34] as well. It is likely that many of the series in which higher HER2 overexpression/amplification frequencies were described have not been unselected, whereas frequencies below 20% have been reported before in unselected series. As our study group concerned consecutive patients, selection bias can be excluded. Furthermore, methodological variation is an 25 ) was similar. This implies that there may be geographic variations in HER-2/neu-and TopoIIa-amplification status. TopoIIa amplification has been described to be present in approximately 5-10% of the total population (about one-third of HER2-amplified tumors), 11 which is consistent with our data (9%).
Co-amplification of HER2 and TopoIIa was seen in 42% of cases (low and high level) in line with previous studies that reported co-amplification rates of 32-57%. 10, 11 We found no high level amplification of TopoIIa without HER2 amplification, in contrast with some studies that did find TopoIIa amplification with normal HER2 status. 8, 35 However, in some cases we found a low level of TopoIIa gene amplification without any amplification of HER2, but this amplification could not be identified by CISH.
Copy numbers of HER2 were higher than those of TopoIIa, which in addition to the different frequency of amplification of these loci supports the concept that the HER2 gene is the hot spot for amplification on chromosome 17, with lower frequencies of amplification and lower level of amplification of the surrounding genes such as TopoIIa 36 and other chromosome 17q genes included in the kit (as depicted in Figure 2) . Nevertheless, the mechanism of amplification of the HER2 gene and surrounding loci is yet unknown. To which extent these coamplified genes have an impact on response to the HER2-targeted treatment with trastuzumab is unknown.
Eleven patients showed a deletion for TopoIIa by MLPA (3%), which is consistent with literature, where overall prevalence of TopoIIa deletions in breast cancer has varied from 2 to 11% in different studies. 10, 11, 37 In our study, none of these deletions was accompanied by an amplification of HER2. The TOP2A and HER2 gene amplification in breast cancer significance of these deletions is still controversial, but contrary to what was previously thought, 18 one study claimed that it may also predict benefit from treatment with TopoIIa inhibitors. 8 In our study, tumors with gene amplification of Topoisomerase IIa showed evidence of greater expression of topoisomerase IIa protein than did other tumors (P ¼ 0.035), but 4/14 (29%) amplified tumors did not overexpress the TopoIIa protein. All four cases displayed low level amplification by CISH, and two of these four cases were also amplified by MLPA. Previous studies have revealed that, contrary to HER2, where gene amplification is almost always correlated with protein overexpression, TopoIIa gene amplification apparently does not always lead to protein overexpression. 12, 21, 22 Other factors, specifically the tumor proliferation status, may interfere with the TopoIIa protein status as topoisomerase IIa is a marker of proliferation and topoisomerase IIa expression depends on the cell cycle status.
We found, similar to a large previous study, 25 a high concordance between amplification status by MLPA and CISH, which indicates that MLPA is a reliable test for detection of HER-2/neu and TopoIIa amplification. One can even wonder whether MLPA would be suitable as a pre-screening tool alternative to the Hercep test (HER2 immunohistochemistry). Indeed, MLPA is not only easy but also cheaper than CISH. Consumables costs are h11 per reaction compared with h70 per reaction for HER2 CISH and h56 per reaction for TopoIIa CISH. Furthermore, MLPA is more quantitative than immunohistochemistry allowing more straightforward interpretation, and in the same analysis several genes that are important in therapy selection and/or prognosis, such as TopoIIa, can be tested for amplification. Given the inherent molecular complexity of the malignant process, it seems unlikely that the assay of a single marker, regardless of methodology, will ever give us the complete answer as to the response to targeted therapeutics.
Concordance with CISH for TopoIIa was 91%, for HER2 96%. This difference could be due to a more accurate estimation of HER2 status based on three probes instead of only one for TopoIIa in the current kit, indicating that the kit would benefit from more TopoIIa probes. More MLPA probes for TopoIIa could make a more accurate estimate of whether a sample is low level or not amplified. Concordance between MLPA and CISH for HER2 and TopoIIa was highest in MLPA amplified (96 and 100%, respectively) and non-amplified cases (98 and 99%, respectively). For MLPA low-level amplified cases, concordance was low (50 and 16%). However, lowlevel HER2 amplification only occurs in 1-3% of the general population and in 4-25% of the critical group of immunohistochemistry 2 þ carcinomas. 38 These low-level amplified cases probably do not respond as well to HER2-directed therapy as patients showing high level amplifications. 39 Preliminary data from the NSABP B-31 trial, however, suggest that there is a limited subset of patients with tumors that are fluorescence in situ hybridization negative and graded less than immunohistochemistry 3 þ that do achieve significant benefit (P ¼ 0.03) from adjuvant trastuzumab. 40 We therefore re-analyzed our MLPA results with higher cutoff values (than 1.5) between non-amplified and low-level amplified cases (see Table 4 ), which increased the positive predictive value and specificity but decreased the sensitivity of MLPA for both genes. Next to the number of probes and the choice of the cut-off value, another explanation of discrepancies could be the non-morphological aspect of MLPA. Small-amplified clones may be obscured by background non-amplified cells and thereby missed by MLPA. Careful manual microdissection is able to resolve some of the discrepancies, but is not necessary in routine practice and only advisable when tumor percentage is very low (o30%) or extensive ductal carcinoma in situ is present. 41 On the other hand, there were also cases with amplification by MLPA, while CISH was normal. This may be partly due to a lack of sensitivity by CISH for low level amplification.
These data show that MLPA is suited to detect amplification (as well as deletion) of HER2 and TopoIIa in breast cancer patients in one test. Both HER2 and TopoIIa gene alternations have independently been associated with an increased responsiveness to anthracycline-containing chemotherapy regimens relative to non-anthracyline regimens, 42, 43 indicating that measurements of alternations of both genes can guide in the selection of anthracylinecontaining regimens. Furthermore, this MLPA kit contains probes to several other chromosome 17 loci (see Figure 2 ) and can thereby easily determine chromosome 17 polysomy, likely better than using a single in situ hybridization centromere probe, and easier than additional in situ hybridization probes targeted to other chromosome 17 loci. 44 This is even more an advantage, as recently the definition of chromosome 17 polysomy based on CEP17 only is found most questionable. 45 In conclusion, MLPA is an easy and cheaper method to simultaneously detect breast cancer polysomy 17, HER-2/neu and TopoIIa amplification in small quantities of short fragmented DNA extracted from paraffin blocks, and is thereby a good supplementary or even alternative technique to in situ hybridization.
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